Latanoprost Polpharma

Latanoprost, the active ingredient in Latanoprost Polpharma, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure in adults with open‑angle glaucoma and ocular hypertension. GNH USA supplies Latanoprost Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is indicated for conditions affecting ocular pressure and is used in glaucoma management. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma. - Secondary open‑angle glaucoma: helps control pressure when glaucoma is due to another ocular condition.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual brownish pigmentation. - Eye irritation: burning or stinging sensation. - Blurred vision: transient visual disturbance after instillation. - Foreign body sensation: feeling of something in the eye.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, itching, or rash around the eye. - Paradoxical IOP increase: unexpected rise in pressure. - Corneal edema: swelling of the cornea affecting vision. - Ocular infection: risk of bacterial or fungal infection. - Vision loss: rare but possible if complications arise.

Before using Latanoprost, consider the following safety measures. - Assess intra‑ocular pressure: confirm baseline measurements. - Monitor iris color: note any gradual darkening over time. - Avoid use with active ocular infection: postpone treatment until resolved. - Caution in patients with uveitis history: evaluate risk of inflammation. - Do not combine with other prostaglandin analog eye drops: may increase adverse effects. - Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: may amplify side effects. - Combination with systemic carbonic anhydrase inhibitors: can reduce IOP‑lowering efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive pressure‑lowering effect, monitor IOP. - Ocular corticosteroids: may diminish therapeutic response. - Antihistamine eye drops: possible increased ocular irritation.